OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
Sira Nanthapisal, Thanyawee Puthanakit, Peera Jaru-Ampornpan, et al.
Vaccine (2022) Vol. 40, Iss. 18, pp. 2551-2560
Open Access | Times Cited: 14
Sira Nanthapisal, Thanyawee Puthanakit, Peera Jaru-Ampornpan, et al.
Vaccine (2022) Vol. 40, Iss. 18, pp. 2551-2560
Open Access | Times Cited: 14
Showing 14 citing articles:
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis
Alberto San Francisco Ramos, Carolina Liu-Sanchez, Tatiana Bovill Rose, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 266-282
Open Access | Times Cited: 8
Alberto San Francisco Ramos, Carolina Liu-Sanchez, Tatiana Bovill Rose, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 266-282
Open Access | Times Cited: 8
Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: a non-inferiority, randomised, double-blind, phase IV clinical trial in Brazil
Marco Antonio Moreira Puga, Roberto Dias de Oliveira, Patrícia Vieira da Silva, et al.
The Lancet Regional Health - Americas (2025) Vol. 44, pp. 101031-101031
Closed Access
Marco Antonio Moreira Puga, Roberto Dias de Oliveira, Patrícia Vieira da Silva, et al.
The Lancet Regional Health - Americas (2025) Vol. 44, pp. 101031-101031
Closed Access
Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine
Viravarn Luvira, Punnee Pitisuttithum
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 283-293
Open Access | Times Cited: 3
Viravarn Luvira, Punnee Pitisuttithum
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 283-293
Open Access | Times Cited: 3
Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis
Pei Li, Weiwei Wang, Yiming Tao, et al.
Chinese Medical Journal (2023)
Open Access | Times Cited: 4
Pei Li, Weiwei Wang, Yiming Tao, et al.
Chinese Medical Journal (2023)
Open Access | Times Cited: 4
Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster
Tatiana A. do Nascimento, PATRÍCIA YURI NOGAMI, Camille Ferreira de Oliveira, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 792-792
Open Access | Times Cited: 1
Tatiana A. do Nascimento, PATRÍCIA YURI NOGAMI, Camille Ferreira de Oliveira, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 792-792
Open Access | Times Cited: 1
Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents
Pavinee Assavavongwaikit, Napaporn Chantasrisawad, Orawan Himananto, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1098-1098
Open Access | Times Cited: 7
Pavinee Assavavongwaikit, Napaporn Chantasrisawad, Orawan Himananto, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1098-1098
Open Access | Times Cited: 7
Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents
Thanyawee Puthanakit, Rapisa Nantanee, Peera Jaru-Ampornpan, et al.
Vaccine X (2022) Vol. 12, pp. 100211-100211
Open Access | Times Cited: 7
Thanyawee Puthanakit, Rapisa Nantanee, Peera Jaru-Ampornpan, et al.
Vaccine X (2022) Vol. 12, pp. 100211-100211
Open Access | Times Cited: 7
Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
Thanyawee Puthanakit, Napaporn Chantasrisawad, Kirana Yoohat, et al.
Vaccines (2022) Vol. 10, Iss. 10, pp. 1646-1646
Open Access | Times Cited: 7
Thanyawee Puthanakit, Napaporn Chantasrisawad, Kirana Yoohat, et al.
Vaccines (2022) Vol. 10, Iss. 10, pp. 1646-1646
Open Access | Times Cited: 7
Cost effectiveness of fractional doses of COVID-19 vaccine boosters in India
Zhanwei Du, Lin Wang, Yuan Bai, et al.
Med (2023) Vol. 4, Iss. 3, pp. 182-190.e3
Open Access | Times Cited: 3
Zhanwei Du, Lin Wang, Yuan Bai, et al.
Med (2023) Vol. 4, Iss. 3, pp. 182-190.e3
Open Access | Times Cited: 3
Long-term immunogenicity in previously vaccinated healthcare workers with inactivated virus vaccine after SARS-CoV-2 infection or booster vaccination
Varalee Terbsiri, Opass Putcharoen, Gompol Suwanpimolkul, et al.
Vaccine X (2023) Vol. 14, pp. 100334-100334
Open Access | Times Cited: 3
Varalee Terbsiri, Opass Putcharoen, Gompol Suwanpimolkul, et al.
Vaccine X (2023) Vol. 14, pp. 100334-100334
Open Access | Times Cited: 3
Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru
Stephanie Montero, Diego Urrunaga‐Pastor, Percy Soto-Becerra, et al.
Vaccine X (2023) Vol. 14, pp. 100311-100311
Open Access | Times Cited: 3
Stephanie Montero, Diego Urrunaga‐Pastor, Percy Soto-Becerra, et al.
Vaccine X (2023) Vol. 14, pp. 100311-100311
Open Access | Times Cited: 3
Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance
Rapisa Nantanee, Peera Jaru-Ampornpan, Napaporn Chantasrisawad, et al.
Vaccine X (2023) Vol. 15, pp. 100367-100367
Open Access | Times Cited: 2
Rapisa Nantanee, Peera Jaru-Ampornpan, Napaporn Chantasrisawad, et al.
Vaccine X (2023) Vol. 15, pp. 100367-100367
Open Access | Times Cited: 2
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
Sue Ann Costa Clemens, Natalie G. Marchevsky, Sarah Kelly, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 1
Sue Ann Costa Clemens, Natalie G. Marchevsky, Sarah Kelly, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 1
Immunization against COVID-19: A Comprehensive Review on the Leading Vaccines
Ananyaa Srinivasan, Vijaishree Rajesh, Dharani Thamilvanan, et al.
Coronaviruses (2023) Vol. 5, Iss. 4
Closed Access
Ananyaa Srinivasan, Vijaishree Rajesh, Dharani Thamilvanan, et al.
Coronaviruses (2023) Vol. 5, Iss. 4
Closed Access
